Introduction
Recombinant monoclonal antibodies (mAbs) are the best-selling class of biopharmaceutical drugs (Aggarwal, 2011) . They are used in the treatment of a variety of diseases, including many types of cancers, autoimmune diseases, and cardiovascular disorders (Li and Zhu, 2010; Ecker et al., 2015) . Approval and sales rates of therapeutic antibodies have increased progressively and reached nearly $75 billion in 2013 (Walsh, 2014) .
To acquire proper biological functions, cultivated mammalian cell lines are the most preferred hosts for their production, especially Chinese hamster ovary (CHO) cells (Wurm, 2004) . Following random integration of a transgene into the host genome, the rate of gene transcription is related to the chromosomal site of integration, resulting in a position effect (Wilson et al., 1990) . Since most of the mammalian genome is transcriptionally inactive heterochromatin, transgene silencing occurs in large numbers of cells. Several studies have tried to target transgenes in genomic hotspots where high gene expression occurs due to the endogenous sites of open chromatin (Fukushige and Sauer, 1992; Gilbertson, 2003; Ahmadi et al., 2016) . Even if a transgene integrates into the transcriptionally active euchromatin regions, over cultivation time it is silenced as a result of epigenetic processes, such as histone modifications and DNA methylation (Richards and Elgin, 2002; Kwaks and Otte, 2006) . Therefore, achieving high-yielding mammalian cell lines is a challenging issue in the field of cell culture technology. In an effort to overcome this challenge, epigenetic gene regulation tools can be used to protect transgenes from such adverse epigenetic events.
Sodium butyrate (NaBut) and valporonic acid (VPA) are histone deacetylation inhibitors, widely used for recombinant protein production by mammalian cells (Backliwal et al., 2008; Jiang and Sharfstein, 2008) . Histone deacetylase inhibitors (iHDACs) regulate gene expression through histone hyperacetylation, thereby facilitating gene accessibility to transcription factors and improving gene expression (Kwaks and Otte, 2006) . Ubiquitous chromatin-opening elements (UCOEs) are cis-acting epigenetic regulatory elements, derived from promoter regions of ubiquitously expressed housekeeping genes. They are methylation-free CpG islands and prevent heterochromatin formation and transgene silencing by reducing DNA methylation (Antoniou et al., 2003) . A2UCOE from the human HNRPA2B1-CBX3 locus is one of the most effective UCOEs, and it has been shown that its incorporation into expression vectors can enhance transgene expression levels in mammalian cells (Benton et al., 2002; Williams et al., 2005; Allen and Antoniou, 2007; Boscolo et al., 2012; Nematpour et al., 2017) .
The present study set to compare the influence of NaBut and/or VPA iHDACs and A2UCOE on model mAb omalizumab production in CHO cells. Moreover, the study tried to investigate whether combining these epigenetic tools would also increase mAb production. To this end, first, non-UCOE and UCOE eukaryotic expression plasmids of target antibody were constructed. Then stable CHO cell lines were developed by different vector combinations: non-UCOE vectors (CHO-HL) and UCOE vectors (CHO-UHUL). Antibody expression was analyzed using western blot analysis, and binding activity of purified antibody was tested using enzyme-linked immunosorbent assays (ELISA). Omalizumab is a recombinant anti-IgE antibody that interacts with circulating IgE and interrupts the allergic cascade. Recombinant test mAb function was compared with commercial omalizumab using direct ELISA. Finally, the cells were cultured in the presence or absence of NaBut and VPA and mAb production was compared using ELISA.
Materials and methods

Construction of antibody-coding vectors
In this investigation, the humanized IgG 1 mAb omalizumab (drug bank database ID: DB00043) was used as a model antibody. The antibody consists of two identical heavy and two identical light polypeptide chains. The sequences of both heavy and light chains were commercially synthesized by Genscript (Piscataway, NJ, USA). The A2UCOE sequence was obtained from NCBI epigenomics browser (accession number: NC_000007.13) and was commercially synthesized by Genscript.
Each of the antibody chains were cloned into separate expression vectors under the control of the same human cytomegalovirus (CMV) immediate-early enhancer and promoter. The heavy chain sequence was ligated into pTracer-CMV2 vector (Invitrogen, Carlsbad, CA, USA) using KpnI and NotI sites. The light chain sequence was ligated into the pIRES2-DsRed2 vector (Clontech, Mountain View, CA, USA) using NheI and EcoRI sites on the vector and insert sequence. Heavy and light chain coding vectors were named PH and PL, respectively. The A2UCOE sequence was obtained from the pUC-57 vector using Genscript. It was ligated into the upstream of the CMV promoter in the PH and PL vectors using SgrDI and NruI sites and ApaLI and NdeI sites, respectively. These UCOE-containing vectors were termed PUH and PUL, respectively. All cloning steps were done based on standard cloning methods (Sambrook and Russell, 2001 ). The cloned sequences were confirmed by DNA sequencing. 2.2. Cell culture CHO-DG44 host cell line (Life Technologies, Carlsbad, CA, USA) (Catalog no: A10971-01) was used for mAb production. Cells were cultivated in chemically defined, protein-free CD CHO medium (Gibco, Carlsbad, CA, USA), supplemented with 8 mM L-glutamine (Gibco), 0.1% Pluronic F-68 (Gibco), and 1% penicillin/streptomycin (100 µg/mL) (Gibco) at 37 °C and 5% CO 2 in disposable vented T75 flasks and subcultured every 3 days at a density of 3-5 × 10 5 cells/mL. The cell concentration and viability were determined by 0.4% Trypan Blue (Sigma-Aldrich, St. Louis, MO, USA) staining assay using hemacytometer, and all counts were performed in duplicate and averaged (Tennant, 1964) .
Transfection and generation of stable cell lines
Transfection was carried out in duplicate in 6-well tissue culture plates; for each well, 2 × 10 6 cells were seeded and transfected with 3 µg of linearized plasmid DNA, using Xtream HD reagent (Roche, Basel, Switzerland) according to the manufacturer's instructions.
To generate stable cell lines, CHO cells were first transfected with LC-expressing vectors (PL or PUL) and selected with G418 (400 µg/mL) (Sigma-Aldrich) 72 h posttransfection over 14 days. Then the resulting LC-expressing stable cells were transfected with HCexpressing vectors (PH or PUH) and selected with zeocin (500 µg/mL) (Gibco) 72 h posttransfection over 14 days. Stable cell lines were generated using different antibody vector combinations: 1) CHO-HL transfected with PH and PL vectors and 2) CHO-UHUL transfected with PUH and PUL vectors.
NaBut and VPA treatment
Stocks of 1 M NaBut and 500 mM VPA (Sigma-Aldrich) were prepared in PBS and sterilized with a 0.22-mm filter. The working concentrations of NaBut and VPA were optimized and further added at concentrations of 2 mM and 500 µM, respectively. To analyze antibody productivity, 1 × 10 6 cell/mL were seeded in 6-well tissue culture plates in Pro CHO5 medium (Lonza, Basel, Switzerland) supplemented with 100 mM hypoxanthine, 16 mM thymidine (Sigma-Aldrich), and 8 mM glutamine and grown under shaking at 125 rpm. CHO-HL and CHO-UHUL cell lines were cultured in the presence and absence of NaBut or VPA, and antibody yields were determined using ELISA after 5 days of treatment.
2.5. Antibody purification mAb was purified using Protein A affinity chromatography. Aliquots with a density of 1 × 10 6 cell/mL were seeded in 125 mL shake flasks in Pro CHO5 medium (Lonza) with supplements and grown under shaking at 125 rpm for 5 days. The culture media of stable cell lines were collected at the end of batch culture, centrifuged at 7000 rpm for 20 min, filtered, and then loaded on a Protein A column packed with MabSelect (GE Healthcare, Piscataway, NJ, USA). The column was washed with washing buffer (PBS, pH of 7) and eluted with elution buffer (sodium citrate, pH of 4) (Merck, Kenilworth, NJ, USA). Fractions were collected in 1-mL tubes and stored at -20 °C for further analysis.
Western blot analysis
The quality and specificity of antibody expression were characterized using western blot analysis. Culture supernatants or purified samples of stably transfected CHO pools were subjected to standard reducing or nonreducing 12% polyacrylamide gel SDS-PAGE, followed by electrophoretic transfer onto nitrocellulose membrane (GE Healthcare) using a Trans-Blot SD semidry transfer cell (BioRad, Hercules, CA, USA). The nitrocellulose membrane was washed with PBS supplemented with 0.025% [v/v] Tween 20 and blocked overnight with 5% skimmed milk in PBS at 4 °C. After the washing step, the samples were stained with horseradish peroxidase (HRP)-conjugated goat antihuman IgG at 1:5000 in PBS (SigmaAldrich) at room temperature for 2 h and developed using DAB Peroxidase Substrate (Sigma-Aldrich). Standard human IgG with known concentration was used as a control.
Binding activity of purified antibody
Model mAb omalizumab is an anti-IgE and interrupts the allergic cascade via binding to circulating IgE. Specific binding of the recombinant test mAb to the IgE antigen was investigated using direct ELISA and compared with a commercial mAb. Briefly, 100 µL of the purified recombinant test mAb, commercial omalizumab as a positive control, rituximab as a nonspecific control antibody, and bovine serum albumin (BSA) as a negative control were applied to the microtest wells containing IgE antibody (Abcam, Cambridge, UK) in triplicate and incubated for 1 h at 37 °C. After the washing step, 100 µL of polyclonal HRP-conjugated goat antihuman IgG detector antibody (Sigma-Aldrich) was added and incubated for 1 h at 37 °C. Then the substrate was added to each well and incubated at room temperature for 30 min. Finally, the reaction was stopped and the samples were read at 450 nm using a PowerWave XSTM (BioTek, Winooski, VT, USA) microplate reader.
Antibody quantification
Recombinant mAb concentration was measured using sandwich ELISA. Multiwell strips (Thermo Fisher Scientific, Boston, MA, USA; Nunc) were coated with 100 µL of polyclonal rabbit antihuman IgG Fc capture antibody (Thermo Fisher Scientific, Pierce) at a 1:16,000 dilution in coating buffer (50 mM NaHCO 3 , pH 9) and incubated overnight at 4 °C. The wells were washed three times with washing buffer (PBS supplemented with 0.025% [v/v] Tween 20), and blocked with 150 µL of PBS containing 1% (w/v) BSA for 1 h at 37 °C. Following five washes, 100 µL of sample culture supernatant (diluted in PBS if necessary) was loaded into wells in duplicate and incubated for 1 h at 37 °C. After another washing step, 100 µL of polyclonal HRP-conjugated goat antihuman IgG detector antibody (Sigma) at a 1:32,000 dilution in washing buffer was added and incubated for 1 h at 37 °C. The washing step was repeated and 100 µL of tetramethylbenzidine peroxidase substrate was added and proceeded at room temperature in the dark for 30 min. To stop the reaction, 100 µL 1N H 2 SO 4 was added, and absorbance at 450 nm was measured using a PowerWave XSTM (BioTek) microplate reader. In all experiments, a standard curve was generated using standard human IgG (Genscript).
Results
Expression of the recombinant mAb
In this study, two stable cell lines were generated by different vector combinations: CHO-HL generated via PL and PH vectors, and CHO-UHUL generated via PUL and PUH vectors. After several passages, the expression of transfected cells in culture supernatants was examined via western blot analysis. Under reducing conditions, the appearance of bands with the expected size of 25 KD for light chain and 50 KD for heavy chain verified the presence of antibody (Figure 1). 
Binding activity of the purified antibody
It is crucial that the recombinant test mAb have its correct biological function. To investigate the biological activity of expressed antibody in generated cell lines, the antibody was purified by Protein A affinity chromatography. In SDS-PAGE analysis, the presence of 25 KD light chain and 50 KD heavy chain bands (Figure 2A ) in reducing conditions and a 150 KD whole antibody band in nonreducing conditions confirmed the quality of purified antibody ( Figure 2B ). The binding activity of purified antibody to IgE was tested and compared with that of commercial omalizumab using direct ELISA. BSA was used as a negative control and Rituximab was used as a nonspecific control antibody. 
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mAb from both CHO-HL and CHO-UHUL was the same (data not shown).
The effect of UCOE on mAb expression
To evaluate the impact of UCOE on antibody production in CHO cells, non-UCOE-and UCOE-expressing cells were constructed. The non-UCOE CHO-HL expressed both antibody chains without UCOE regulation and was used as a control. The CHO-UHUL expressed HC and LC under the UCOE control and was used as a UCOE system. Following stable transfection and selection with G418 and zeocin, expression levels were compared using ELISA. Cells were maintained at a density of 1 × 10 6 cells/mL in 6-well tissue culture plates in Pro CHO5 medium (Lonza) with supplements, and cell-free supernatants were collected after 5 days. Figure 4 indicates that UCOE-containing cells have significantly higher antibody expression than non-UCOE cells. The expression levels of CHO-HL and CHO-UHUL were 0.34 mg/L and 1.2 mg/L, respectively. Moreover, the cell viability of UCOE and non-UCOE was similar: about 60%. In accordance with previous investigations, these data indicate that the inclusion of UCOE on antibody chains leads to substantially higher mAb productivity in CHO cells.
The effect of NaBut and VPA iHDACs on mAb expression
In order to assess the effect of iHDACs on antibody production, CHO-HL and CHO-UHUL cells were cultivated in the presence and absence of NaBut (2 Mm) or VPA (500 µM). A total of 1 × 10 6 cells/mL were grown in 6-well tissue culture plates in Pro CHO5 medium (Lonza) with supplements and antibody titers were calculated after 5 days using ELISA. Treatment of cells with NaBut and VPA improved mAb yields about 2-fold in CHO-HL and 2.5-fold in CHO-UHUL cell lines ( Figure 5 ). As depicted in Figure 5 , VPA treatment increased antibody expression levels slightly more than NaBut, and the cell viability for VPA treated cells was similar to that of the untreated control, but the viability of NaBut-treated cells dramatically decreased. Therefore, it seems that VPA treatment is more beneficial than NaBut for antibody production. Moreover, antibody production from UCOEcontaining cells generally remained higher than non-UCOE cell pool over iHDACs treatment ( Figure 5 ), which represents the synergic effect of A2UCOE, NaBut, and/or VPA.
Discussion
Chemical iHDACs, including NaBut and VPA, are frequently employed for the production of recombinant proteins by mammalian cells (Backliwal et al., 2008; Jiang and Sharfstein, 2008; Rodrigues Goulart et al., 2010; Hong et al., 2014) . These compounds nonspecifically regulate gene expression and have various effects on cell metabolism (Wippermann et al., 2016) . UCOE acts as a cis-acting DNA element and may specially improve the expression of surrounded transgene (Williams et al., 2005) . In this study, the responses of mAb-expressing CHO cells to NaBut or VPA iHDACs and UCOE were evaluated, and in the second part of the study, the combined effect of iHDACs and UCOE on antibody production was investigated. For this purpose, UCOE and non-UCOE vectors were constructed for an antibody expression model and evaluated in stably transfected CHO-DG44 cells. CHO-HL expressed both heavy and light chains without UCOE regulation, and CHO-UHUL expressed both antibody chains in the presence of UCOE.
Following the generation of stable cell lines, antibody expression was confirmed at the protein level using western blot. The recombinant test mAb function from both generated cell lines was similar to the commercial antibody. Comparison of antibody levels using ELISA revealed that the insertion of UCOE in mAb-coding vectors enhances antibody yields at least four-fold without influencing the viability of CHO cells. Further antibody expression was investigated in the presence or absence of iHDACs in the developed cell lines. Treatment of antibody-expressing CHO-HL and CHO-UHUL cells with NaBut and VPA increased expression 2-and 2.5-fold greater compared to control cells, respectively. UCOE as a cis-acting enhancer improved antibody expression more efficiently without any side effects on cell growth characteristics, which is crucial in industrial antibody production. On the other hand, iHDACs regulated gene expression nonspecifically and decreased cellular density and viability. NaBut decreased cell viability about 60%, which may have been due to its cytotoxic effect on these cells. In some studies, NaBut treatment frequently led to apoptosis and decreased cell growth (Davie, 2003; Mariani et al., 2003; Kobayashi et al., 2004) . Since expression enhancement was slightly higher in VPA treatment than in NaBut and because of the cytotoxic effect of NaBut, it was suggested that VPA is more beneficial for antibody expression upregulation than NaBut.
UCOE and iHDACs could raise antibody expression, and expression enhancement of UCOE has been reported to be 2-fold greater than NaBut and VPA treatment. Furthermore, there was an additive effect when NaBut or VPA was used in combination with UCOE. Accordingly, the use of UCOE combined with VPA is recommended as an optimized system for mAb expression enhancement in CHO cells. Moreover, the findings may have significant implications for the design of mAb expression systems through employing epigenetic tools. work was supported by a grant from the Pasteur Institute of Iran. . Antibody expression levels of generated cell lines. CHO-HL and CHO-UHUL cells were seeded in 6-well tissue culture plates at a density of 10 6 cell/mL and antibody yields were examined using ELISA [Section 2.8]. The error bars represent standard deviation of two independent assays of each sample. . Antibody expression levels in untreated control and NaBut-and VPA-treated CHO-HL and CHO-UHUL cells. Stable cell lines were cultured in the presence and absence of NaBut or VPA, and antibody yields were determined using ELISA [Section 2.4]. The error bars represent standard deviation of two independent assays of each sample.
